Complement Factor H (CFH) is a pivotal regulator of the complement system, integral to maintaining immune homeostasis and protecting host tissues from undue complement‐mediated damage. By inhibiting ...

RGC-32, or Response Gene to Complement 32, plays a pivotal role in mediating cellular responses following complement activation. Acting as a regulator of the cell cycle, RGC-32 is implicated in ...

Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

Researchers have developed a diagnostic chip that analyzes leukocyte adhesion to detect cancer recurrence and evaluate ...